PSY: Whole Slide Imaging System
What it covers
The whole slide imaging system is an automated digital slide creation, viewing, and management system intended as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed, paraffin-embedded (FFPE) tissue. The system generates digital images that would otherwise be appropriate for manual visualization by conventional brightfield microscopy. The whole slide imaging system is not intended for use with slides prepared from frozen tissue, cytology, and non-FFPE hematopathology specimens (e.g., peripheral blood smear).
FDA’s definition of product code PSY, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K253554 | Aperio GT 450 DX; Aperio GT 180 DX | Leica Biosystems Imaging, Inc. | Aug 7, 2026 | Traditional |
| K260964 | NanoZoomer S540MD Slide Scanner System | Hamamatsu Photonics K.K. | Jul 22, 2026 | Abbreviated |
| K251952 | Virasight | Virasoft Corporation | Jul 17, 2026 | Traditional |
| K253606 | NanoZoomer S20MD Slide scanner system; NanoZoomer S360MD Slide scanner system | Hamamatsu Photonics K.K. | Jul 15, 2026 | Abbreviated |
| K243871 | Philips IntelliSite Pathology Solution 5.1 | Philips Medical Systems Nederland B.V. | Mar 6, 2025 | Traditional |
| K241717 | E1000 Dx Digital Pathology Solution | Shandon Diagnostics Limited | Feb 28, 2025 | Traditional |
| K242783 | Roche Digital Pathology Dx | Ventana Medical Systems, Inc. | Dec 17, 2024 | Special |
| K242848 | Philips IntelliSite Pathology Solution 5.1 | Philips Medical Systems Nederland B.V. | Dec 10, 2024 | Traditional |
| K241871 | Philips IntelliSite Pathology Solution | Philips Medical Systems Nederland B.V. | Dec 2, 2024 | Traditional |
| K233204 | Philips IntelliSite Pathology Solution 5.1 | Philips Medical Systems Nederland B.V. | Jun 24, 2024 | Traditional |
Clearances by year
23 PSY 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 4 | 253 |
| 2025 | 2 | 169 |
| 2024 | 9 | 265 |
| 2023 | 1 | 88 |
| 2022 | 1 | 288 |
| 2021 | 2 | 205 |
| 2019 | 2 | 63 |
| 2017 | 2 | 105 |
Who submits
11 applicants cleared a PSY device since 2011. 35% of the clearances went to applicants in Netherlands, then United States (35%), Japan (17%) and Belgium (4%). By type: Traditional 65%, Abbreviated 22%, Special 9% and Direct 4%.
| Applicant | Clearances since 2011 |
|---|---|
| Philips Medical Systems Nederland B.V. | 7 |
| Hamamatsu Photonics K.K. | 4 |
| Leica Biosystems Imaging, Inc. | 3 |
| Ventana Medical Systems, Inc. | 2 |
| Barco N.V. | 1 |
| Indica Labs, Inc. | 1 |
| Philips Electronics Nederland B.V. | 1 |
| Proscia, Inc. | 1 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) Premarket notification submissions must include the following information:
(i) The indications for use must specify the tissue specimen that is intended to be used with the whole slide imaging system and the components of the system.
(ii) A detailed description of the device and bench testing results at the component level, including for the following, as appropriate:
(A) Slide feeder;
(B) Light source;
(C) Imaging optics;
(D) Mechanical scanner movement;
(E) Digital imaging sensor;
(F) Image processing software;
(G) Image composition techniques;
(H) Image file formats;
(I) Image review manipulation software;
(J) Computer environment; and
(K) Display system.
(iii) Detailed bench testing and results at the system level, including for the following, as appropriate:
(A) Color reproducibility;
(B) Spatial resolution;
(C) Focusing test;
(D) Whole slide tissue coverage;
(E) Stitching error; and
(F) Turnaround time.
(iv) Detailed information demonstrating the performance characteristics of the device, including, as appropriate:
(A) Precision to evaluate intra-system and inter-system precision using a comprehensive set of clinical specimens with defined, clinically relevant histologic features from various organ systems and diseases. Multiple whole slide imaging systems, multiple sites, and multiple readers must be included.
(B) Reproducibility data to evaluate inter-site variability using a comprehensive set of clinical specimens with defined, clinically relevant histologic features from various organ systems and diseases. Multiple whole slide imaging systems, multiple sites, and multiple readers must be included.
(C) Data from a clinical study to demonstrate that viewing, reviewing, and diagnosing digital images of surgical pathology slides prepared from tissue slides using the whole slide imaging system is non-inferior to using an optical microscope. The study should evaluate the difference in major discordance rates between manual digital (MD) and manual optical (MO) modalities when compared to the reference (e.g., main sign-out diagnosis).
(D) A detailed human factor engineering process must be used to evaluate the whole slide imaging system user interface(s).
(2) Labeling compliant with 21 CFR 809.10(b) must include the following:
(i) The intended use statement must include the information described in paragraph (b)(1)(i) of this section, as applicable, and a statement that reads, “It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using this device.”
(ii) A description of the technical studies and the summary of results, including those that relate to paragraphs (b)(1)(ii) and (iii) of this section, as appropriate.
(iii) A description of the performance studies and the summary of results, including those that relate to paragraph (b)(1)(iv) of this section, as appropriate.
(iv) A limiting statement that specifies that pathologists should exercise professional judgment in each clinical situation and examine the glass slides by conventional microscopy if there is doubt about the ability to accurately render an interpretation using this device alone.
From 21 CFR 864.3700. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 864.3700 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PSY clearances declared.
Ask about PSY
Questions about PSY
What is FDA product code PSY?
Product code PSY, “Whole Slide Imaging System” in FDA's classification database, is a Class II device type under 21 CFR 864.3700 (whole slide imaging system), reviewed by FDA's Pathology panel. FDA's 510(k) database lists 23 clearances under PSY, 23 of them since 2011.
How many 510(k) clearances are there under PSY?
FDA’s 510(k) database listed 23 clearances under PSY as of Oct 29, 2026, 23 of them decided since 2011; the most recent decision was Aug 7, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a PSY 510(k)?
For the 9 PSY clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 158 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most PSY clearances?
Since 2011: Philips Medical Systems Nederland B.V. (7), Hamamatsu Photonics K.K. (4), Leica Biosystems Imaging, Inc. (3), Ventana Medical Systems, Inc. (2) and Barco N.V. (1). 11 applicants have cleared a PSY device in that time.